# PROCEPT BioRobotics Corporation (PRCT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $22.76, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). PROCEPT BioRobotics Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.8×**. Each dollar of revenue is priced at 3.8×.
- **Price / book: 3.8×**. The shares trade at 3.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.6%** (5-yr avg -6.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 64.2%**. PROCEPT BioRobotics Corporation keeps 64.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -33.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -31.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -26.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -68.9%**. Return on all capital, debt included, is -68.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -21.6%**. Each dollar of assets produces -21.6% of profit.

## Growth
- **Revenue growth (1 yr): 37.2%** (3-yr 60.1%/yr, 5-yr 109.0%/yr). Revenue grew 37.2% over the last year, against 109.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1.7%**. Earnings per share rose 1.7%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.14**. Debt is 0.14 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.2×**. It would take 2.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 6.41**. A Z-score of 6.41 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. PROCEPT BioRobotics Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (11 analysts). 11 analysts cover PROCEPT BioRobotics Corporation; the consensus is hold, with an average price target of $21.64 (-5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -40.6%** (YTD -27.7%, 3-mo -18.2%). The shares are down 40.6% over twelve months including dividends.
- **From 52-week high: -45.2%** (36.6% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.83** (volatility 63%). Beta of 0.83 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRCT · Page: https://foliofundamentals.com/stocks/prct

Not investment advice.